Verbatim response from Perplexity
No telehealth services currently legally offer compounded GLP-1s as a standard, compliant product after the FDA’s 2026 crackdown, because the FDA has explicitly restricted the use of GLP-1 ingredients in non-approved compounded drugs and issued 30 warning letters to companies (including Hims & Hers) for illegally marketing them as equivalents to FDA-approved drugs like Ozempic or Wegovy [2][8].
The FDA’s stance is that compounded GLP-1s are not safe, effective, or of consistent quality compared to approved versions, and claims of “sameness” or “generic” status violate the Federal Food, Drug, and Cosmetic Act [3][5]. While Hims & Hers was previously a major provider of such compounded versions (at ~$49/month), the FDA has signaled moves to restrict their ingredient access and potentially refer the company to the Department of Justice [8].
A potential future change may occur if HHS Secretary Robert F. Kennedy Jr.’s proposal to reclassify 14 restricted peptides (which could include some GLP-1-related substances) is adopted, potentially allowing lawful compounding again under stricter clinical channels—but this is not yet in effect [6]. Until then, any telehealth provider offering compounded GLP-1s is likely operating in violation of current FDA enforcement policy.
Specific recommendation: If you seek GLP-1 therapy, choose FDA-approved options through licensed providers like:
- Novo Nordisk (Wegovy, Ozempic) via primary care or weight-loss specialists.
- Eli Lilly (Mounjaro, Zepbound) via telehealth platforms that prescribe only approved medications (e.g., Ro (Roman Health), Lemon Health, or K Health).
Avoid platforms still advertising compounded versions (like Hims & Hers) until regulatory clarity returns, as they face active legal and enforcement risks [8].